138 related articles for article (PubMed ID: 27102863)
1. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis.
Pyo JS; Kang G; Park K
Int J Biol Markers; 2016 Dec; 31(4):e389-e394. PubMed ID: 27102863
[TBL] [Abstract][Full Text] [Related]
2. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis.
Pyo JS; Sohn JH; Kim WH
Int J Biol Markers; 2016 Feb; 31(1):e1-10. PubMed ID: 26349670
[TBL] [Abstract][Full Text] [Related]
3. Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer.
Ko YS; Kim NY; Pyo JS
Int J Biol Markers; 2018 Jan; 33(1):49-54. PubMed ID: 28478639
[TBL] [Abstract][Full Text] [Related]
4. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis.
Wu SW; Ma CC; Li WH
Diagn Pathol; 2015 Aug; 10():144. PubMed ID: 26276145
[TBL] [Abstract][Full Text] [Related]
5. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review.
Pyo JS; Sohn JH; Kang G
Pathol Oncol Res; 2016 Oct; 22(4):831-7. PubMed ID: 27197524
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis.
Pyo JS; Kang G; Cho WJ; Choi SB
Pathol Res Pract; 2016 Aug; 212(8):710-6. PubMed ID: 27465837
[TBL] [Abstract][Full Text] [Related]
8. Variability in HER2 expression between primary colorectal cancer and corresponding metastases.
Shan L; Lv Y; Bai B; Huang X; Zhu H
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2275-2281. PubMed ID: 30203148
[TBL] [Abstract][Full Text] [Related]
9. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M
Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811
[TBL] [Abstract][Full Text] [Related]
10. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.
Pyo JS; Kang G; Cho H
J Gastric Cancer; 2016 Sep; 16(3):141-151. PubMed ID: 27752391
[TBL] [Abstract][Full Text] [Related]
13. HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.
Seo AN; Kwak Y; Kim WH; Kim DW; Kang SB; Choe G; Lee HS
Virchows Arch; 2015 Jun; 466(6):645-54. PubMed ID: 25739551
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.
Seo AN; Kwak Y; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
PLoS One; 2014; 9(5):e98528. PubMed ID: 24879338
[TBL] [Abstract][Full Text] [Related]
15. Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole - tissue sections.
Kılıçarslan A; Dogan HT; Süngü N; Dogan M; Yalcin A; Dede DŞ
Pol J Pathol; 2018; 69(2):143-149. PubMed ID: 30351861
[TBL] [Abstract][Full Text] [Related]
16. HER2 immunohistochemical scores provide prognostic information for patients with HER2-type invasive breast cancer.
Tsai YF; Tseng LM; Lien PJ; Hsu CY; Lin YS; King KL; Wang YL; Chao TC; Liu CY; Chiu JH; Yang MH
Histopathology; 2019 Mar; 74(4):578-586. PubMed ID: 30515868
[TBL] [Abstract][Full Text] [Related]
17. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
[TBL] [Abstract][Full Text] [Related]
18. Correlated non-nuclear COX2 and low HER2 expression confers a good prognosis in colorectal cancer.
Zhou FF; Huang R; Jiang J; Zeng XH; Zou SQ
Saudi J Gastroenterol; 2018; 24(5):301-306. PubMed ID: 29873317
[TBL] [Abstract][Full Text] [Related]
19. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.
Lei YY; Huang JY; Zhao QR; Jiang N; Xu HM; Wang ZN; Li HQ; Zhang SB; Sun Z
World J Surg Oncol; 2017 Mar; 15(1):68. PubMed ID: 28327158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
